Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
FOSTER CITY, Calif., Feb. 15, 2017 -- PointCross Life Sciences came out of stealth mode with its Xbiom™ Insights solution for Clinical Biomarker research. With two clients deployed, PointCross is now acquiring new pharma and biotechnology companies who are pursuing precisely targeted therapies in oncology, central nervous system, and cardiovascular. Having proven the capability and value to researchers over the past year, the company has now formally launched its Xbiom™ big data platform.
“Semantically integrating four normally disconnected data sources – clinical data, biomarker data, bio-sample availability, and bioinformatics registry data – into a single point from where researchers can search, stratify cohorts, correlate and analyze clinical findings against biomarkers in minutes is a paradigm changing capability for both big pharma as well as smaller biotech companies,” says Dr. Suresh Madhavan, CEO at PointCross.
The Xbiom™ platform is built on a proven stack of big data technologies, including PointCross' underlying Orchestra® technology with a robust big data stack that is serving the pharmaceutical industry with its petabyte scale. This stack includes Hadoop HDFS, Spark, Cassandra, Lucene/SOLR, and Hive that support the Orchestra® ontology, collaboration, Role Based Access Control and Semantic Data Exchange engines. It is available for big pharma who need users and applications to access the data within Xbiom™. It is also available as a SaaS solution, suitable for smaller biotech firms.
The Xbiom™ platform serves the R&D and Regulatory needs in both non-clinical and clinical development lifecycle as well as biomarker R&D to support translational and precision medicine development. In addition to the Xbiom™ Insights-Clinical Biomarker solution, PointCross also offers Xbiom™ Insights-Nonclinical, Xbiom™ Regulatory-Clinical, and Xbiom™ Regulatory-Nonclinical solutions.
About PointCross Life Sciences
PointCross Life Sciences provides the life sciences industry with data management, analytics and visualization solutions that reduce risks, improve data quality, shorten time to market, and generate better insights from R&D and regulatory data. We are a strategic solution provider to the FDA and to several major Biopharma companies. PointCross was recognized in 2013 as one of Gartner’s Cool Vendors in Life Sciences.
Press Contact: Kunaal Madhavan, Marketing at PointCross Life Sciences www.pointcrosslifesciences.com [email protected]
